Obesity Clinical Trial
Official title:
Mind/Body Stress Management to Improve Outcomes in Workplace Weight Loss Programs
Verified date | February 2016 |
Source | Alere Wellbeing |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
The purpose of this study is to explore the efficacy of a phone-based weight loss program
that has stress management techniques integrated throughout (Weight Talk-Mindfulness). The
program is targeted at employees of certain companies who meet a cut-off score on a measure
of stress-related eating. The control group will receive a standard phone-based program with
no additional stress management information (Weight Talk-Standard).
- Hypothesis 1: Participants in Weight Talk-Mindfulness (WT-M; n=50) will experience
decreases in their stress-related & emotion-related eating compared to the Weight
Talk-Standard (WT-S; n=25) group.
- Hypothesis 2: The WT-M group will lose more weight compared to the WT-S control group.
- Hypothesis 3: Participants in WT-M will experience decreased perceived stress,
increased eating self-efficacy, increased acceptance of weight-related thoughts &
feelings and increased mindfulness compared to those in the WT-S control arm.
- Hypothesis 4: Participants in WT-M will be equally as satisfied with their weight loss
program as those in WT-S.
Status | Completed |
Enrollment | 75 |
Est. completion date | January 2016 |
Est. primary completion date | January 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Be enrolled in the Weight Talk program, inclusion criteria: - Employment by one of the employers who contract for Weight Talk services - Being over 18 years of age - Speak and read English - Have a starting BMI between 25 and 35. - Score 5 or higher on the 8-item Internal Disinhibition subscale of the Eating Inventory. - Have regular access to email and internet. - Willingness and ability to complete study and intervention procedures, including completing assessments, engaging in moderate physical activity (e.g., walking, swimming) and using the electronic scale at least once per week. Exclusion Criteria: - Type 2 Diabetes (Type 1 is an exclusion for the Weight Talk program). - Past diagnosis of anorexia nervosa or bulimia nervosa. - Weight Talk program exclusion criteria include: - Pregnancy - Bariatric surgery within past 12 months or planned in the next 6 months - Undergoing dialysis - Have Type 1 Diabetes diagnosis - Women who are pregnant are not eligible for the program, but contraception is not required as this is a low risk study - Currently using or planning to start using a pharmaceutical weight loss drug |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Alere Wellbeing, Inc | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
Alere Wellbeing |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Mindful Eating Questionnaire | 28-item scale that measures non-judgmental awareness of physical and emotional sensations associated with eating. | Screening, 6-month follow-up | No |
Other | Rapid Fruit and Vegetable Screener | 10-item scale that assesses fruit and vegetable intake. | Screening, 6-month follow-up | No |
Other | Fat Screener | 17-item scale that assesses fat intake | Screening, 6-month follow-up | No |
Other | Sweets Eating | 2-item scale that assesses high sugar food and drink intake | Screening, 6-month follow-up | No |
Other | Perceived Stress Scale - 4 item | a 4-item scale that evaluates the appraisal of stress in one's life | Screening, 6-month follow-up | No |
Other | Binge Eating Scale | 16-item scale that assesses the presence of binge eating behaviors. | Screening, 6-month follow-up | No |
Other | Behavioral Obesity Phenotype Scale | 8-item scale that assesses lack of control, lack of satiation, and preoccupation with food. We include 6 out of the 8 original items; 2 of the items already exist in the Binge Eating Scale (BES). One additional Preoccupation with Food item was added. | Screening, 6-month follow-up | No |
Other | Acceptance and Action Questionnaire for Weight Related Difficulties | 22-item scale that measures acceptance and flexibility in relation to problematic thoughts and feelings regarding weight. | Screening, 6-month follow-up | No |
Other | Generalized Anxiety Disorder scale | 7-item diagnostic scale that assesses an individual's severity of anxiety and is used as a clinical screening tool for generalized anxiety disorder. | Screening, 6-month follow-up | No |
Other | Personal Health Questionnaire | 2-item scale that assesses the frequency of depressed mood over the past 2 weeks and is used as a preliminary screening tool for depression. | Screening, 6-month follow-up | No |
Other | Adapted Physical Activity Measure | 11-item scale that assesses overall activity level over the past week, adapted from measure used in the National Health and Nutrition Examination Survey (NHANES) | Screening, 6-month follow-up | No |
Other | Five Facet Mindfulness Questionnaire: Short Form | 24-item scale that measures non-judgmental awareness of thoughts, feelings, and physical sensations. | Screening, 6-month follow-up | No |
Other | Satisfaction and Adherence | 11-item measure consisting of Likert scale and open-ended questions about the participants' experience with the intervention and their adherence to mindfulness practice assignments. | 6-month follow-up | No |
Primary | Eating Inventory - Internal Disinhibition subscale | 8 items, screens for emotion and stress-related eating habits | Screening and 6-month follow-up | No |
Secondary | Body weight | Weight in pounds | Screening and 6-month follow-up | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |